TY - JOUR
T1 - A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and
T2 - Neisseria meningitidis outer membrane vesicles
AU - Santana-Mederos, Darielys
AU - Perez-Nicado, Rocmira
AU - Climent, Yanet
AU - Rodriguez, Laura
AU - Ramirez, Belinda Sanchez
AU - Perez-Rodriguez, Sonia
AU - Rodriguez, Meybi
AU - Labrada, Claudia
AU - Hernandez, Tays
AU - Diaz, Marianniz
AU - Orosa, Ivette
AU - Ramirez, Ubel
AU - Oliva, Reynaldo
AU - Garrido, Raine
AU - Cardoso, Felix
AU - Landys, Mario
AU - Martinez, Roselyn
AU - Gonzalez, Humberto
AU - Hernandez, Tamara
AU - Ochoa-Azze, Rolando
AU - Perez, Jose L.
AU - Enriquez, Juliet
AU - Gonzalez, Nibaldo
AU - Infante, Yenicet
AU - Espinosa, Luis A.
AU - Ramos, Yassel
AU - González, Luis Javier
AU - Valenzuela, Carmen
AU - Casadesus, Ana Victoria
AU - Fernandez, Briandy
AU - Rojas, Gertrudis
AU - Pérez-Massón, Beatriz
AU - Tundidor, Yaima
AU - Bermudez, Ernesto
AU - Plasencia, Claudia A.
AU - Boggiano, Tammy
AU - Ojito, Eduardo
AU - Chiodo, Fabrizio
AU - Fernandez, Sonsire
AU - Garcia-Rivera, Dagmar
AU - Fang, Cheng
AU - Chen, Guang-Wu
AU - Rivera, Daniel G.
AU - Valdes-Balbin, Yury
AU - Garcia-Rivera, Dagmar
AU - Verez Bencomo, Vicente
N1 - Funding Information: We thank Rolando Pérez, Luis Herrera, Agustin Lage and Eduardo Martinez (BioCubaFarma) for advice and support to the project, and Lila Castellanos for scientific advice and corrections. We are grateful to Fondo de Ciencia e Innovación, CITMA-Cuba (Project FONCI 2020-20) and DAAD, Germany (Project GLACIER 57592717), for financial support. Funding Information: We thank Rolando P?rez, Luis Herrera, Agustin Lage and Eduardo Martinez (BioCubaFarma) for advice and support to the project, and Lila Castellanos for scientific advice and corrections. We are grateful to Fondo de Ciencia e Innovaci?n, CITMA-Cuba (Project FONCI 2020-20) and DAAD, Germany (Project GLACIER 57592717), for financial support. Publisher Copyright: © The Royal Society of Chemistry.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its receptor-binding domain (RBD) with the host's cellular receptor. Vaccines seek to block this interaction by eliciting neutralizing antibodies, most of which are directed toward the RBD. Many protein subunit vaccines require powerful adjuvants to generate a potent antibody response. Here, we report on the use of a SARS-CoV-2 dimeric recombinant RBD combined with Neisseria meningitidis outer membrane vesicles (OMVs), adsorbed on alum, as a promising COVID-19 vaccine candidate. This formulation induces a potent and neutralizing immune response in laboratory animals, which is higher than that of the dimeric RBD alone adsorbed on alum. Sera of people vaccinated with this vaccine candidate, named Soberana01, show a high inhibition level of the RBD-ACE2 interaction using RBD mutants corresponding to SARS-CoV-2 variants of concern and wild-type expressed using the phage display technology. To our knowledge, this is the first time that the immunostimulation effect of N. meningitidis OMVs is evaluated in vaccine candidates against SARS-CoV-2.
AB - SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its receptor-binding domain (RBD) with the host's cellular receptor. Vaccines seek to block this interaction by eliciting neutralizing antibodies, most of which are directed toward the RBD. Many protein subunit vaccines require powerful adjuvants to generate a potent antibody response. Here, we report on the use of a SARS-CoV-2 dimeric recombinant RBD combined with Neisseria meningitidis outer membrane vesicles (OMVs), adsorbed on alum, as a promising COVID-19 vaccine candidate. This formulation induces a potent and neutralizing immune response in laboratory animals, which is higher than that of the dimeric RBD alone adsorbed on alum. Sera of people vaccinated with this vaccine candidate, named Soberana01, show a high inhibition level of the RBD-ACE2 interaction using RBD mutants corresponding to SARS-CoV-2 variants of concern and wild-type expressed using the phage display technology. To our knowledge, this is the first time that the immunostimulation effect of N. meningitidis OMVs is evaluated in vaccine candidates against SARS-CoV-2.
UR - http://www.scopus.com/inward/record.url?scp=85125102975&partnerID=8YFLogxK
U2 - https://doi.org/10.1039/d1cb00200g
DO - https://doi.org/10.1039/d1cb00200g
M3 - Article
C2 - 35360883
SN - 2633-0679
VL - 3
SP - 242
EP - 249
JO - RSC Chemical Biology
JF - RSC Chemical Biology
IS - 2
ER -